Guardian Connect system

Sensor, Glucose, Invasive

FDA Premarket Approval P160007

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the guardian connect system. The guardian connect system is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The guardian connect system provides real-time glucose values and trends through a guardian connect app installed on a compatible consumer electronic mobile device. It allows users to detect trends and track patterns in glucose concentrations. The guardian connect app alerts if a guardian sensor (3) glucose level reaches, falls below, rises above, or is predicted to surpass set values. The guardian sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the guardian sensor (3). The guardian connect system is comprised of the following devices: guardian connect app, guardian sensor (3), and the guardian connect transmitter. Guardian sensor (3):the guardian sensor (3) is intended for use with medtronic diabetes glucose-sensing systems, to continuously monitor glucose levels in persons with diabetes. The guardian sensor (3) is indicated for 7 days of continuous use. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. Guardian connect transmitter:the guardian connect transmitter is intended for use with the guardian connect system. The guardian connect transmitter powers the glucose sensor, collects and calculates sensor data, and sends the data via bluetooth version 4. 0 to the guardian connect app installed on a compatible mobile device. The transmitter is only compatible with the guardian sensor (3). The transmitter is indicated for multiple uses on a single patient as a component of the guardian connect system. The guardian connect transmitter requires a prescription. Guardian connect app:the guardian connect app is intended for use only by patients using a compatible mobile device, and who have sufficient experience to adjust mobile device audio and notification settings. The app displays sensor glucose data, and also provides a user interface for sensor calibration, entering data such as exercise and meals, and uploading information to the carelink personal website. It allows users to detect trends and track patterns in glucose concentrations. The guardian connect app provides alerts if a guardian sensor (3) glucose level reaches, falls below, rises above, or is predicted to surpass set values. The guardian connect app is available over-the-counter (otc) but requires the guardian sensor (3) and guardian connect transmitter to function.

DeviceGuardian Connect system
Classification NameSensor, Glucose, Invasive
Generic NameSensor, Glucose, Invasive
ApplicantMEDTRONIC MINIMED
Date Received2016-03-08
Decision Date2018-03-08
Notice Date2018-04-10
PMAP160007
SupplementS
Product CodeMDS
Docket Number18M-1371
Advisory CommitteeClinical Chemistry
Expedited ReviewNo
Combination Product No
Applicant Address MEDTRONIC MINIMED 18000 Devonshire Street northridge, CA 91325-1219
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P160007Original Filing
S046 2022-11-04 30-day Notice
S045
S044 2022-04-01 30-day Notice
S043
S042 2021-11-17 Special (immediate Track)
S041 2021-09-20 30-day Notice
S040 2021-01-27 Special (immediate Track)
S039 2020-11-03 30-day Notice
S038
S037 2020-08-04 30-day Notice
S036 2020-05-26 30-day Notice
S035
S034 2020-01-08 30-day Notice
S033 2019-11-29 30-day Notice
S032
S031 2019-11-27 30-day Notice
S030 2019-11-27 30-day Notice
S029
S028 2019-10-17 30-day Notice
S027 2019-10-11 30-day Notice
S026
S025 2019-08-21 30-day Notice
S024 2019-07-15 30-day Notice
S023 2019-06-19 30-day Notice
S022 2019-05-21 30-day Notice
S021 2019-05-17 30-day Notice
S020
S019
S018
S017 2019-04-03 30-day Notice
S016 2019-02-25 30-day Notice
S015 2019-02-11 30-day Notice
S014
S013 2019-02-01 30-day Notice
S012
S011 2018-11-02 30-day Notice
S010 2018-10-15 30-day Notice
S009 2018-07-09 30-day Notice
S008 2018-07-02 30-day Notice
S007 2018-06-19 30-day Notice
S006 2018-06-07 Special (immediate Track)
S005 2018-05-31 30-day Notice
S004 2018-05-18 Real-time Process
S003 2018-05-11 30-day Notice
S002 2018-03-29 30-day Notice
S001 2018-03-26 30-day Notice

NIH GUDID Devices

Device IDPMASupp
00763000186333 P160007 000
00763000455651 P160007 000
00763000408886 P160007 000
00763000408893 P160007 000
00763000455682 P160007 000
00763000455668 P160007 000
00763000455675 P160007 000
00763000516239 P160007 000
00763000399009 P160007 000
00763000398330 P160007 000
00763000285852 P160007 000
00763000179601 P160007 000
20763000179629 P160007 000
00763000002596 P160007 000
00763000002602 P160007 000
00763000158392 P160007 000
00763000348021 P160007 000
00763000388379 P160007 003
00763000381103 P160007 029
00763000381097 P160007 029
00763000337049 P160007 036
00763000337001 P160007 036
00763000388379 P160007 037
00763000388355 P160007 037

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.